Ad is loading...
CVGRX
Price
$45.90
Change
-$1.01 (-2.15%)
Updated
Nov 15 closing price
GAFFX
Price
$80.09
Change
-$1.35 (-1.66%)
Updated
Nov 15 closing price
Ad is loading...

CVGRX vs GAFFX

Header iconCVGRX vs GAFFX Comparison
Open Charts CVGRX vs GAFFXBanner chart's image
Calamos Growth A
Price$45.90
Change-$1.01 (-2.15%)
VolumeN/A
CapitalizationN/A
American Funds Growth Fund of Amer F3
Price$80.09
Change-$1.35 (-1.66%)
VolumeN/A
CapitalizationN/A
CVGRX vs GAFFX Comparison Chart
Loading...
View a ticker or compare two or three
VS
CVGRX vs. GAFFX commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CVGRX is a StrongBuy and GAFFX is a StrongBuy.

FUNDAMENTALS
Fundamentals
GAFFX has more cash in the bank: 298B vs. CVGRX (1.59B). GAFFX pays higher dividends than CVGRX: GAFFX (0.75) vs CVGRX (0.00). CVGRX was incepted earlier than GAFFX: CVGRX (34 years) vs GAFFX (8 years). CVGRX is a more actively managed with annual turnover of: 57.00 vs. GAFFX (31.00). CVGRX has a lower initial minimum investment than GAFFX: CVGRX (2500) vs GAFFX (1000000). CVGRX (29.26) and GAFFX (28.41) have marching annual gain over last year. GAFFX return over 5 years is better than : 54.44 vs. CVGRX (37.84).
CVGRXGAFFXCVGRX / GAFFX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence34 years8 years-
Gain YTD28.53526.825106%
Front LoadN/AN/A-
Min. Initial Investment250010000000%
Min. Initial Investment IRAN/AN/A-
Net Assets1.59B298B1%
Annual Yield % from dividends0.000.75-
Returns for 1 year29.2628.41103%
Returns for 3 years-2.96-3.7878%
Returns for 5 years37.8454.4470%
Returns for 10 years-10.04N/A-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ENLC15.490.16
+1.04%
Enlink Midstream LLC
PRLD1.040.01
+0.97%
Prelude Therapeutics
RELX44.45-1.50
-3.26%
Relx PLC
AKBA1.79-0.07
-3.76%
Akebia Therapeutics
VRDN20.14-1.50
-6.93%
Viridian Therapeutics